BTK inhibitors as first line treatment in mantle cell lymphoma: a debate
Dr. Jeanette Doorduijn, hematologist at the Erasme hospital in Rotterdam participated in the debate on whether BTK inhibitors should be used as first line treatment in mantle cell lymphoma. She summarised the pro/cons based on the Triangle and the Shine trial and shed her light on current and future management of mantle cell lymphoma in daily practice.
With the educational support of:
